Focus Partners Wealth
ACRV icon

Focus Partners Wealth’s Acrivon Therapeutics ACRV Stock Holding History

Focus Partners Wealth’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,846
Closed -$988K – 2648
2025
Q3 		$988K Buy
+19,846
New +$27.9K ﹤0.01% 1292

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Focus Partners Wealth's ACRV Position: Q4 2025 in Review

Focus Partners Wealth sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 19,846 shares — an estimated $988K sold.

Focus Partners Wealth first reported a position in ACRV in Q3 2025 and held it in 1 quarter. The position peaked at $988K in Q3 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

  • Focus Partners Wealth reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 19,846 Acrivon Therapeutics shares in Q4 2025, an estimated $988K.
  • Focus Partners Wealth first reported a position in Acrivon Therapeutics in Q3 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Acrivon Therapeutics position peaked at $988K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on Focus Partners Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.